 NEW HAVEN, Conn., June 23, 2021 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. the Company Nasdaq: BTAI, a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 3,155,000 shares of common stock at a public offering price of 31.70 per share. In addition, a related party stockholder, BioXcel LLC, has granted the underwriters a 30-day option to purchase up to an additional 473,250 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to the Company from the offering are expected to be approximately 100.0 million, before deducting underwriting discounts and commissions and offering expenses. The Company will not receive any of the proceeds from any sale of shares in this offering by BioXcel LLC. 